Broker tips: Dr Martens, Barratt Redrow
By Iain Gilbert
Date: Thursday 27 Feb 2025
(Sharecast News) - Analysts at Berenberg initiated coverage on iconic bootmaker Dr Martens on Thursday with a 'buy' rating and 102.0p price target, noting that the business had both "global appeal and clear growth potential".
Berenberg said Dr Martens was a "distinctive footwear brand" with global relevance that stretches far beyond its workwear and counter-cultural roots in the UK.
"We estimate that slightly less than 18% of Dr Martens' total revenues are generated in the UK, where it has circa 1% share of the total footwear market," said the analysts. "On a global basis, we estimate that Dr Martens has only 0.0003% market share and we think that there is clear scope to build its presence further worldwide."
The German bank said the brand itself had "a high level of awareness", as 74% of consumers in the markets in which the company trades said they were aware of it, with brand awareness highest in the UK at 92%, versus 73% in the US and 53% in Japan.
"Dr Martens favours a direct-to-consumer approach but also values the wholesale distribution channel. The company's expansion from its current reach could include circa 15 new stores pa for DTC, together with new wholesale partnerships," said Berenberg, which also pointed out that large countries and regions such as India, South Africa and the Middle East represent "virgin territory" for the company.
Deutsche Bank upgraded Barratt Redrow on Thursday to 'buy' from 'hold' following the sharp drop in the share price since last August.
It said Barratt's interims set a positive tone, with the group saying that current trading was solid and guiding to adjusted FY25 pre-tax profit towards the top of consensus.
"We have increased our FY25 PBT forecast by 5%, but leave outer years broadly unchanged," the bank said. "Medium-term guidance suggests a strong rebuild of profits in future years, supported by a recovering outlet profile and synergies from the Redrow deal.
However, Deutsche noted that medium-term return targets suggested a "meaningfully lower" return on equity than pre-Covid levels, in keeping with the wider industry.
Deutsche said Barratt was trading broadly in line with current NTA, suggesting little recovery has being priced in. It said its unchanged target price of 536.0p equates to 1.16x FY27 P/NTA and points to 24% potential upside.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN